2nd Quarter - Report

FORBES-TATE for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Re-authorization of the Pandemic and All-Hazards Preparedness Act; NDAA - provisions related to biological and chemical defense; Department of Defense appropriations for Medical Countermeasures; FDA regulatory issues; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, Naloxone access, and co-prescribing/opioid prescribing guidelines.

Contacted: Office of Natl Drug Control Policy (NDCP); Centers For Disease Control & Prevention (CDC); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Justice, Dept of (DOJ); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.